Decades in the making, Kyowa Hakko Kirin finally wins FDA approval for add-on Parkinson's therapy
More than two decades after Kyowa Hakko Kirin kicked off the clinical evaluation of its Parkinson’s disease drug, the Japanese pharma group has finally secured FDA approval.
The drug, istradefylline, targets the adenosine A2A receptor, which is located in the basal ganglia — understood to play a key role in controlling voluntary movement. It was approved by the FDA as an add-on treatment to levodopa/carbidopa on Tuesday. The drug was cleared for use in Japan back in 2013.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
